首页> 外文期刊>Reviews on Recent Clinical Trials >Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
【24h】

Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer

机译:分子靶向药物联合化学放射治疗局部晚期宫颈癌

获取原文
获取原文并翻译 | 示例
           

摘要

Despite improvements in survival after the introduction of chemo-radiotherapy (CRT) in the treatment of patients with cervical cancer, loco-regional control of this disease continues to be a major problem. The present article reviews current and emerging therapeutic strategies combining CRT with novel molecular agents that specifically target the abnormal tumor microenvironment, with the aim of improving local control and survival in patients with locally advanced cervix cancer.nnThe evidence supporting the biological rational to combine novel non-cytotoxic agents with CRT is strong, and drugs targeting different molecular pathways are currently under clinical development (EGFR inhibitors, COX-2 inhibitors, hypoxia targeted agents, etc). Early pre-clinical and clinical strategies also favor the use of vascular-targeted agents with the aim to normalize the abnormal tumor vasculature, increase tumor oxygenation, and reduce interstitial fluid pressure (IFP). The integration of these novel targeted therapies with CRT in clinical trials is discussed, as well as new and promising biomarkers to test drug activity
机译:尽管在采用化学放射疗法(CRT)治疗子宫颈癌患者后存活率有所提高,但是对该病的局部控制仍然是一个主要问题。本文综述了目前和新兴的将CRT与新型分子药物相结合的治疗策略,这些分子药物专门针对异常的肿瘤微环境,目的是改善局部晚期宫颈癌患者的局部控制和生存率。具有CRT的细胞毒性药物很强,并且针对不同分子途径的药物目前正在临床开发中(EGFR抑制剂,COX-2抑制剂,低氧靶向药物等)。早期的临床前和临床策略也倾向于使用以血管为靶标的药物,目的是使异常的肿瘤脉管系统正常化,增加肿瘤的氧合和降低间质液压力(IFP)。讨论了这些新颖的靶向疗法与CRT在临床试验中的整合,以及用于测试药物活性的新的有前途的生物标志物

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号